

RECEIVED/ #4  
AUG 06 2001 8-7-01

EXPRESS MAIL CERTIFICATE

Date 8/1/01 Label EL903057865-US

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Name (Print) Daisy Perez

Signature Daisy Perez

Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No.: 1728/1F088-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ick-Dong Yoo *et al.*

Serial No.: 09/846,634

Confirmation No.:

Filed: May 1, 2001

For: NOVEL IMMUNO-STIMULATING POLYSACCHARIDE SUBSTANCE FROM PHELLINUS SPP. STRAIN AND USE THEREOF

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of  
Patents and Trademarks  
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form PTO-1449. Under 37C.F.R. §1.98(d) copies of the references cited in the PTO-1449 form are not included because each reference was cited in an office action of the parent application: U.S. Patent Application No. 09/221,261, filed December 28, 1998.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that


each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

This submission is filed before a first action on the merits has been mailed and, so, it is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge the above deposit account for any deficiency.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Tom Triolo', written over a horizontal line.

Thomas Triolo, Ph.D.  
Registration No. 48,001  
Agent for Applicant(s)

Dated: August 1, 2001

DARBY & DARBY  
805 Third Avenue  
New York, NY 10022  
(212) 527-7700